Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Lorbrena
|
| gptkbp:chemicalFormula |
C22H24Cl2N4O2S
|
| gptkbp:clinicalTrials |
combination therapy
Phase 3 monotherapy NCT01970865 NCT03052608 |
| gptkbp:compatibleWith |
high
|
| gptkbp:contraindication |
weight gain
hyperglycemia pneumonitis cardiac issues severe hepatic impairment vision changes concurrent use of strong CYP3A4 inducers hypersensitivity to lorlatinib |
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:endOfLife |
about 24 hours
|
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:future_plans |
Phase 1
Phase 2 |
| gptkbp:hasPopulation |
adults
pediatric patients |
| https://www.w3.org/2000/01/rdf-schema#label |
Lorlatinib
|
| gptkbp:is_monitored_by |
electrocardiogram
liver function tests complete blood count blood glucose levels |
| gptkbp:lastProduced |
2018
|
| gptkbp:mandates |
gptkb:ALK-positive_metastatic_non-small_cell_lung_cancer
ROS1-positive metastatic non-small cell lung cancer |
| gptkbp:marketedAs |
2018
|
| gptkbp:patentStatus |
patented
|
| gptkbp:releaseYear |
2014
|
| gptkbp:researchFocus |
ROS1 resistance mutations
ALK_resistance_mutations |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea peripheral neuropathy elevated liver enzymes |
| gptkbp:storage |
store at room temperature
|
| gptkbp:suitableFor |
100 mg once daily
|
| gptkbp:targets |
gptkb:ALK_gene
ROS1 gene |
| gptkbp:triggerType |
inhibitor_of_ALK_and_ROS1
|
| gptkbp:usedFor |
treatment of non-small cell lung cancer
|
| gptkbp:waterManagement |
urine
bile |
| gptkbp:weight |
466.43 g/mol
|